<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00377650</url>
  </required_header>
  <id_info>
    <org_study_id>JagiellonianU</org_study_id>
    <nct_id>NCT00377650</nct_id>
  </id_info>
  <brief_title>Polish-Italian-Hungarian RAndomized ThrombEctomy Trial</brief_title>
  <official_title>Polish-Italian-Hungarian RAndomized ThrombEctomy Trial. PIHRATE Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jagiellonian University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jagiellonian University</source>
  <brief_summary>
    <textblock>
      Aim Primary percutaneous coronary intervention efficacy improvement by DIVER CE thrombectomy
      system leading to thrombus reduction.

      Study design:

      Multicenter, prospective, opened, randomized.

      Primary endpoints:

      ST resolution &gt;70% 60 minutes after PCI

      Secondary endpoints:

      Thrombectomy system efficacy/passing trough lesion with thrombus reduction according do TIMI
      thrombus scale ≥ 1 TIMI 3 flow after PCI MBG 3 CMR – infarct size, measurement of left
      ventricular end-diastolic EDV and end-systolic volumes ESV and ejection fraction (EF) ECHO:
      measurement of left ventricular end-diastolic EDV and end-systolic volumes ESV, ejection
      fraction (EF) and wall motion score index (WMSI) Major cardiac events /cardiac death, reMI,
      rePCI (TVR, TLR, non infarct involved vessel) or CABG/ 6 month follow up Rate of composite
      angiographic adverse events including: distal embolisation, transient no-reflow or slow flow,
      final TIMI &lt;3, need of bail out GpIIb/IIIa inhibitors or adenosine or nitroprosside, final
      thrombus score &gt;1
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2005</start_date>
  <completion_date>December 2007</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ST resolution &gt;70% 60 minutes after PCI</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Thrombectomy system efficacy/passing trough lesion with thrombus reduction according do TIMI thrombus scale ≥ 1</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TIMI 3 flow after PCI</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MBG 3</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CMR – infarct size, measurement of left ventricular end-diastolic EDV and end-systolic volumes ESV and ejection fraction (EF)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECHO: measurement of left ventricular end-diastolic EDV and end-systolic volumes ESV, ejection fraction (EF) and wall motion score index (WMSI)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major cardiac events /cardiac death, reMI, rePCI (TVR, TLR, non infarct involved vessel) or CABG/ 6 month follow up</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of composite angiographic adverse events including: distal embolisation, transient no-reflow or slow flow, final TIMI &lt;3, need of bail out GpIIb/IIIa inhibitors or adenosine or nitroprosside, final thrombus score &gt;1</measure>
  </secondary_outcome>
  <enrollment>200</enrollment>
  <condition>Myocardial Infarction</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Percutaneous thrombectomy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ST elevation acute myocardial infarction within 6 hours since pain onset, with 2 mm ST
             segment elevation in two lead

          -  Minimum 3 mm ST segment elevation in one leads

          -  Vessel reference diameter &gt; 2.5 mm

          -  When vessel reference diameter ≥ 4,0 mm than additional distal protection device
             (filter) is needed during stent implantation

        Exclusion Criteria:

          -  Contraindications to PCI (contrast allergy, no possibility to stent implantation) ASA,
             thienopirydins or GP IIb/IIIa inhibitors

          -  Active bleeding or coagutopathy

          -  Prior CABG or PCI

          -  Known ejection fraction EF &lt;35%

          -  Cardiogenic shock /SBP &lt; 90 mmHg, IABP and/or catheloamins usage/

          -  LBBB, pacemaker rhythm

          -  Severe calcifications

          -  Previous Myocardial infarction

          -  Stroke history

          -  Patient directly after reanimation

          -  Known thrombocytopenia- platelets &lt; 100 000

          -  Pregnancy

          -  Cancer disease

          -  No future patient cooperation expected

          -  Patient’s taking part in the other clinical trials

          -  Fibrynolisis directly administered before PCI

          -  Renal insufficiency (creatynine &gt; 220 µmol/ml), hemodialysis

          -  Contraindications to PCI (contrast allergy, no possibility to stent implantation) ASA,
             thienopirydins or GP IIb/IIIa inhibitors

          -  Active bleeding or coagutopathy

          -  Prior CABG or PCI

          -  Known ejection fraction EF &lt;35%

          -  Cardiogenic shock /SBP &lt; 90 mmHg, IABP and/or catheloamins usage/

          -  LBBB, pacemaker rhythm

          -  Severe calcifications

          -  Previous Myocardial infarction

          -  Stroke history

          -  Patient directly after reanimation

          -  Known thrombocytopenia- platelets &lt; 100 000

          -  Pregnancy

          -  Cancer disease

          -  No future patient cooperation expected

          -  Patient’s taking part in the other clinical trials

          -  Fibrynolisis directly administered before PCI

          -  Renal insufficiency (creatynine &gt; 220 µmol/ml), hemodialysis

          -  Liver insufficiency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dariusz Dudek, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jagiellonian University Medical College</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dariusz Dudek, MD</last_name>
    <phone>124247181</phone>
    <phone_ext>+48</phone_ext>
    <email>mcdudek@cyf-kr.edu.pl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute, Medical School of University Pecs</name>
      <address>
        <city>Pecs</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivan Horvath, MD</last_name>
      <email>ivan.g.horvath@aok.pte.hu</email>
    </contact>
    <investigator>
      <last_name>Ivan Horvath, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardiology Department Hospital Villascassi</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo Rubartelli, MD</last_name>
      <email>paolo.rubartelli@villascassi.it</email>
    </contact>
    <investigator>
      <last_name>Paolo Rubartelli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute of Cardiology, Catholic University</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Burzotta, MD</last_name>
      <email>f.burzotta@rm.unicatt.it</email>
    </contact>
    <investigator>
      <last_name>Francesco Burzotta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Górnośląskie Centrum Medyczne</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrzej Ochala, Md</last_name>
      <email>aochala@poczta.onet.pl</email>
    </contact>
    <investigator>
      <last_name>Andrzej Ochała, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zaklad Hemodynamiki i Angiokardiohrafii IK CMUJ</name>
      <address>
        <city>Krakow</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Waldemar A Mielecki, MD</last_name>
      <phone>124247181</phone>
      <phone_ext>+48</phone_ext>
      <email>wmielecki@su.krakow.pl</email>
    </contact>
    <investigator>
      <last_name>Dariusz Dudek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Waldemar A Mielecki, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oddział Kardiologii Inwazyjnej, Elektroterapii i Angiologii NZOZ</name>
      <address>
        <city>Nowy Sacz</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renata Korpak-Wysocka, MD</last_name>
      <phone>184407487</phone>
      <phone_ext>+48</phone_ext>
    </contact>
    <investigator>
      <last_name>Renata Korpak-Wysocka, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dawid Giszterowicz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Szpital Wojewódzki w Przemyślu</name>
      <address>
        <city>Przemyśl</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrzej Wiśniewski, MD</last_name>
      <phone>166775000</phone>
      <phone_ext>+48</phone_ext>
    </contact>
    <investigator>
      <last_name>Andrzej Wiśniewski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instytut Kardiologii im.Prymasa Tysiaclecia Sefana Kardynala Wyszynskiego</name>
      <address>
        <city>Warszawa</city>
        <zip>04-628</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Witkowski, MD</last_name>
      <email>witkowski@hbz.pl</email>
    </contact>
    <investigator>
      <last_name>Adam Witkowski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Slaskie Centrum Chorob Serca</name>
      <address>
        <city>Zabrze</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariusz Gasior, MD</last_name>
      <email>m.gasior@sccs.pl</email>
    </contact>
    <investigator>
      <last_name>Mariusz Gasior, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>January 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2006</study_first_submitted>
  <study_first_submitted_qc>September 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2006</study_first_posted>
  <last_update_submitted>January 16, 2007</last_update_submitted>
  <last_update_submitted_qc>January 16, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 17, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

